
Literaturverzeichnis

- ¹ Pihnsch R. Die Therapie mit oralen Cumarin-Derivaten-Hämostaselogie Medizinische Klinik III. Klinikum Großhadern München, 1993.
- ² Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med. 1993; 95:315-328.
- ³ Levine MN, Raskob G, Landefeld SC, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995; 108:276-289.
- ⁴ Van der Meer FJM, Rosendaal FR, Vandenbroucke W, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost. 1996;76: 12-16.
- ⁵ Arbeitsgruppe der DGVS. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten. Zeitschrift für Gastroenterologie 1996, 34: 392 – 401.
- ⁶ Thomson R, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 1998;316:509-51.
- ⁷ Kluge, Friedrich. Adolf Kußmaul 1822 – 1902. Arzt und Forscher - Lehrer der Heilkunst. Rombach Verlag KG, Freiburg/D., 2003.
- ⁸ Frühmorgen P. Gastroenterologische Endoskopie: Ein Leitfaden zur Diagnose und Therapie. Springer Verlag, Berlin Heidelberg New York, 1998.
- ⁹ Ulrich, B. Die Bedeutung der Panendoskopie für die Tumorausbreitungsdiagnostik bei Tumoren im Kiefer- und Gesichtsbereich. Med. Dissertation Universität Tübingen, 2003.
- ¹⁰ Reifferscheid M, Weller S. Chirurgie. Georg Thieme Verlag Stuttgart, New York, 1989.
- ¹¹ Anonymus, kma-Magazin, www.klinikmanagementaktuell.de
- ¹² Sieg A, Hachmöller-Heisenbach U, Heisenbach T. Häufigkeit interventionspflichtiger Komplikationen in der ambulanten Endoskopie in Deutschland: Eine prospektive Untersuchung in gastroenterologischen Fachpraxen. Verdauungskrankheiten, 17;1999; 80-86.
- ¹³ Casais P, Luceros AS, Meschengieser S, Fondevila C, Santarelli MT, Lazzari MA. Bleeding risk factors in chronic oral anticoagulation with acenocoumarol. Am J Hematol 2000; 63(4):192-196.
- ¹⁴ Palareti G. (ISCOAT Investigator Group). Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348(9025):423-428.

- ¹⁵ Thomopoulos KC, Mimidis KP, Theocharis GJ, Gatopoulou AG, Kartalis GN, Nikolopoulou VN. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: Endoscopic findings, clinical management and outcome. *World J Gastroenterol* 2005;11(9):1365-1368.
- ¹⁶ Schettler G, Greten H. *Innere Medizin*. Georg Thieme Verlag Stuttgart, New York 1990.
- ¹⁷ Kreiss C, Blum AL. Epidemiologie und Risikofaktoren der gastroduodenalen Ulcuskrankheit. *Chirurgie* 1996; 67(1):7-13.
- ¹⁸ Choudari CP, Raigopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. *Gut* 1994;35(4):464-466.
- ¹⁹ Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving longterm anticoagulant therapy. *Am J Med* 1988;84(4):683-690.
- ²⁰ Reinhold CH R. Epidemiologie der peptischen Ulkusblutung im zeitlichen Verlauf. Dissertation an der Med. Fakultät der Heinrich-Heine- Universität Düsseldorf, 2004.
- ²¹ Primatesta P, Goldacre MJ, Seagroatt V. Changing patterns in the epidemiology and hospital care of peptic ulcer. *Int J Epidemiol* 1994; 23(6),1206-1217.
- ²² Sonnenberg A. Factors which influence the incidence and course of peptic ulcer. *Scand J Gastroenterol Suppl* 1988; 155: 119-140.
- ²³ Gilbert DA. Epidemiology of upper gastrointestinal bleeding *Gastrointest Endosc* 1990; 36: 8S.
- ²⁴ Vaira D, Menagatti M, Miglioli M. What is the role of *Helicobacter pylori* in complicated ulcer disease?. *Gastroenterology* 1994; 113(suppl.1)78-84.
- ²⁵ Laine L, Peterson WL. Bleeding peptic ulcer. *N. Eng J Med*. 1994; 331; 717-727.
- ²⁶ Schriftreihe "Therapieempfehlungen" des ITZ Tübingen ISSN 1438-8979 Magenkarzinom S.1 Autorenkollektiv, 1999.
- ²⁷ Wörterbuch der Medizin, Verlag Volk und Wissen 1984, 12. Auflage
- ²⁸ Goldinger A. Therapie mit Cumarinderivaten. *Krankenhauspharmazie* 1996;17:198-209.
- ²⁹ Garfield S. *Mauve - How a man invented a colour that changed the world*. Faber + Faber, London 2000.
- ³⁰ Van den Besselaar AM. International normalized ratio: towards improved accuracy. *Thromb Haemostasis* 1999; 82(6):1562-1563.

-
- ³¹ Burri S, Demarmets-Biasiutti F, Lämmle B, Wuillemin WA. Vergleich der Quick-/INR-Werte aus kapillärem Vollblut (CoaguChek®Plus) und venösem Citratplasma bei Patienten mit und ohne orale Antikoagulation. *Schweiz Med Wochenschr* 1998; 128:1723-9.
- ³² Dirckx JH, Armand J. Quick: pioneer and prophet of coagulation research. *Ann Intern Med*. 1980;92(4):553-8.
- ³³ Schmitt, Y. *Praktische Probleme in der Therapie mit Antikoagulantien*. Darmstadt, 2003.
- ³⁴ Hull R, Hirsch J, Jay R. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. *N Engl J Med* 1982; 307:1676-1681.
- ³⁵ Hylek EM, Go AS, Chang Y, Jensvold NG, Henault LE, Selby JV, Singer DE. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003; 349: 1019-1026.
- ³⁶ The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. *N Engl J Med* 1995; 333: 5-10.
- ³⁷ Deutsche Gesellschaft für vaskuläre und endovaskuläre Chirurgie, Leitlinien zur Bein- und Beckenvenenthrombose, Artikel/AWMF-Leitlinien, 07.09.2004, Register Nr. 004/021, <http://www.awmf-leitlinien.de/gefäßchirurgie>, aufgesucht am 19.5.2006
Leitlinien zur Diagnostik und Therapie der akuten Thrombosen der tiefen Bein- und Beckenvenen, <http://www.awmf-leitlinien.de/angiologie>, aufgesucht am 19.5.2006
- ³⁸ Van de Loo JCW, Stenziger W. Antithrombotic prophylaxis in arterial and venous vessel diseases, *Fibrinolysis* 1995; 9-58, Suppl.1.
- ³⁹ Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *JAMA* 1999, 282, 2058-67.
- ⁴⁰ Hurlen M, Erikssen J, Smith P, Arnesen H, Rollag A. Comparison of bleeding complications of warfarin and warfarin plus acetylsalicylic acid: a study in 3166 outpatients. *J Intern Med* 1994; 236:299-304.
- ⁴¹ Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, Aspirin, or Both after Myocardial Infarction. *N Engl J Med* 2002; 347:969-974.
- ⁴² Beyth RJ, Landefeld CS. Anticoagulants in older patients: a safety perspective. *Drugs Aging* 1995; 6: 45-54.
- ⁴³ Kidd M, Modlin IM. A century of *Helicobacter pylori*. Paradigms lost - paradigms regained. *Digestion* 1998;59:1-15.

-
- ⁴⁴ Mitchell HM, Li YY, Hu Pj, Liu Q, Chen M, Du GG, Wang ZJ, Lee A, Hazell SL. Epidemiology of *Helicobacter pylori* in Southern China; Identification of early childhood as the critical period for acquisition. *J Infect Dis* 1992;166(1):149-53.
- ⁴⁵ Pounder, R.E, Ng,D. The prevalence of *Helicobacter pylori* infection in different countries. *Aliment Pharmacol.Ther* 1995;9(S2):33-39.
- ⁴⁶ Malfertheiner P, Nilius M. Pathogenese der *Helicobacter pylori*-Infektion. In: Malfertheiner P (Hrsg.): *Helicobacter pylori: Von der Grundlage zur Therapie*. Thieme Verlag, Stuttgart, New York 1994; 1.Aufl: 11-18.
- ⁴⁷ Stolte M. Pathologie der *Helicobacter pylori*-Krankheiten In: Malfertheimer P(Hrsg.); *Helicobacter pylori - Von der Grundlage zur Therapie*. Thieme, Stuttgart, New York 1994; 1.Aufl, 23-44.
- ⁴⁸ Forman D, Newell DG, Fullerton F, Yarnell JWG, Stacey AR, Wald N, Sitas F. Association between infection with *Helicobacter pylori* and risk of gastric cancer: evidence from a prospective investigation. *Brit Med J* 1991; 302:1302-5.
- ⁴⁹ Parsonett J, Friedmann GD, Vandersteen DP, Chan Y, Vogelmann JH, Orentreich H, Sibley R. *Helicobacter pylori* infection and the risk of gastric carcinoma. *N Eng J Med* 1991; 325: 1127-31.
- ⁵⁰ Caspary WF, Rösch W. Diagnostik und Therapie der *Helicobacter-pylori*-Infektion. *Dtsch Ärzteblatt* 1996;93:A2094-2097.
- ⁵¹ Silverstein FE, Gilbert DA, Tedesco FJ, Buenger NK, Persing J. The national ASGE survey on upper gastrointestinal bleeding. II. Clinical prognostic factors. *Gastrointest Endosc* 1981;27:80-93.
- ⁵² Barkun A, Sabbah S, Enns R, Armstrong D et al. for the RUGBE Investigators. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. *Am J Gastroenterol*. 2004 Jul;99(7):1238-46.
- ⁵³ Jaenecke J. Antikoagulantien- und Fibrinolysetherapie. Georg Thieme Verlag, Stuttgart, New York, 1991.
- ⁵⁴ Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. *Lancet*, 1991 Jan 12;337(8733):85-9.
- ⁵⁵ Weil J, Langman MJS, Wainwright P, Lawson DH, Rawlins M, Logan RFA, Brown TP, Vessy MP, Murphy M, Colin-Jones DG. Peptic ulcer bleeding accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. *Gut* 2000; 46: 27-31.

-
- ⁵⁶ Ray WA, Stein CM, Dangherty JR, Hall K, Arbogast PM, Griffin MR. COX-2 selective non steroidal anti-inflammatory drugs and risk of serious coronary heart disease, *The Lancet*, 2002;360(9339):1071-3.
- ⁵⁷ Langman MJ. Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum, *Ital J Gastroenterol Hepatol* 1999;S1:31.
- ⁵⁸ Jones JI, Hawkey CJ. Physiology and organ-related pathology of the elderly stomach ulcers. *Best Pract Res Clin Gastroenterol* 2001;15: 943-947.
- ⁵⁹ Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: a metaanalysis, *BMJ* 2000; 321.
- ⁶⁰ Frezza M, Gorji N, Melato M. The histopathology of non-steroidal anti-inflammatory drug induced gastroduodenal damage: Correlation with HP, ulcers, and haemorrhagic events. *J.Clin.Pathol.* 2001;54, 521-528.
- ⁶¹ Griffin MR, Scheinan JM. Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity. *Am J Med* 2001; 110 33S.
- ⁶² Van Leerdam ME, Tytgat GNJ. Review article *Helicobacter pylori* infection in peptic ulcer haemorrhage. *Aliment Pharmacol Ther* 2002;16 (Suppl1).
- ⁶³ Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med.* 1991 114(9):735-40.
- ⁶⁴ Kavic SM, Basson MD: Complications of endoscopy. *Am J Surg* 2001; 181-188.
- ⁶⁵ Tinzmann R. ACE-Hemmer verbessern die Nierenfunktion bei Typ-II Diabetikern mit diabetischer Nephropathie durch Suppression der renalen MCP-1 Produktion. Medizinische Dissertation RWTH Aachen 2001.
- ⁶⁶ Altmann D.G. Practical statistics for medical research. Kluwer Academic Publishers, Dordrecht, NL. 1992.
- ⁶⁷ Hilers RD, Bauer P, Schreiber V. Einführung in die Medizinische Statistik. Springer Verlag 2003.
- ⁶⁸ Gordis L. Epidemiologie, Verlag im KILIAN, Marburg 2001; p.132f.
- ⁶⁹ Gigerenzer G, Swijtink Z, Porter T, Daston L, Beatty J, Krüger L. The empire of chance. Cambridge University Press 1989.
- ⁷⁰ Lange St, Bender R. Was ist ein Signifikanztest? Thieme Verlag Stuttgart-New York 2001; 126 T42-T44.
- ⁷¹ Draper N R, Smith H. Applied Regression Analysis, New York , Wiley 1998.

-
- ⁷² Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic Complications of Anticoagulant Treatment. *Chest* 2000;119; 108-121.
- ⁷³ Fihn SD, McDonell D, Martin J, Henikoff D, Vermes D, Kent R. H. White and for the Warfarin Optimized Outpatient Follow-up Study Group. The risk factor for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group. *Ann Intern Med* 1993; 118(7), 511-520.
- ⁷⁴ Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K. Bleeding complications to oral anticoagulant therapy: multivariate analysis of 1010 treatment years in 551 outpatients. *J Intern Med* 1991;229(4):351-355.
- ⁷⁵ van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E.: Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. *Arch Intern Med* 1993; 153(13):1557-1562.
- ⁷⁶ American Society for Gastrointestinal Endoscopy: Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. *Gastrointest Endosc* 1998; 48(6):672-675.
- ⁷⁷ Berersen B, Johnsen R, Straume B, Burhol PU, Jensen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: The Sorreisa Gastrointestinal Disorder Study. *Gut* 1990; 31:989-992.
- ⁷⁸ Farrell JJ, Friedman LS. Gastrointestinal bleeding in older people. *Gastroenterol Clin North Am* 2000; 29(1):1-36.
- ⁷⁹ Struhal W, Doppler G, Berger J, Lenzhofer R. Die Gastroduodenoskopie als Screeninguntersuchung vor oraler Antikoagulationstherapie – Häufigkeit und Altersabhängigkeit blutungsrelevanter pathologischer Befunde. *Acta Medica Austriaca* 3/2003; 80-83.
- ⁸⁰ Linkins LA, Choi PT, Douketis JD. Clinical Impact of Bleeding in Patients Taking Oral Anticoagulant Therapy for Venous Thromboembolism, a Meta-Analysis. *Ann Intern Med*. 2003; 139(11):893-900.
- ⁸¹ Douketis JD, Foster GA, Crowther MA, Ginsberg JS. Clinical factors and timing of recurrent venous thromboembolism during the initial 3 month of anticoagulant therapy. *Arch Intern Med*. 2000; 160:3431-6.
- ⁸² Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors know at the start of outpatient therapy. *Am J Med* 1989; 87:144-152.
- ⁸³ Jaffin BW, Bliss CM, Lamont JT. Significance of occult gastrointestinal bleeding during anticoagulation therapy. *Am J Med* 1987; 83: 269-272.

-
- ⁸⁴ Ayoola EA, al-Rashed RS, al-Mofleh IA, al-Faleh FZ, Laajam M. Diagnostic yield of upper gastrointestinal endoscopy in relation to age and gender: a study of 10112 Saudi patients. *Hepatogastroenterology*. 1996; 43(8):409-15.
- ⁸⁵ Kurata JH, Haile BM, Elashoff JD. Sex differences in peptic ulcer disease. *Gastroenterology*. 1985; 88;1, 96-100.
- ⁸⁶ Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. *J Crit Care*. 2005; 20(1):35-45.
- ⁸⁷ Yoshida K, Matsumoto M, Sugita T, Nishizawa J, Matsuyama K, Tokuda Y, Matsuo T. Gastrointestinal complications in patients undergoing coronary artery bypass grafting. *Ann Thorac Cardiovasc Surg* 2005; 25-28.
- ⁸⁸ Sokic-Milutinovic A, Wex T, Todorovic V, Milosavljevic T, Malfertheiner P. Anti-CagA and anti-VacA antibodies in *Helicobacter pylori*-infected patients with and without peptic ulcer disease in Serbia and Montenegro. *Scand J Gastroenterol*, 2004; 39(3):222-6.
- ⁸⁹ Chang SY, Howden CW. Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease. *Curr Gastroenterol Rep*. 2004; 6(6):447-53.
- ⁹⁰ Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E; Investigators of the Asociacion Espanola de Gastroenterologia (AEG). A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. *Am J Gastroenterol* 2005; 100(8):1685-93.
- ⁹¹ Cryer B. NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. *Am J Gastroenterol* 2005, 100(8):1694-5.
- ⁹² Lanas A. Gastrointestinal injury from NSAID therapy. How to reduce the risk of complications. *Postgrad Med*. 2005; 117(6):23-8, 31.
- ⁹³ Thomsen RW, Riis A, Christensen S, Nørgaard M, Sørensen HAT. Diabetes and 30-Day Mortality From Peptic Ulcer Bleeding and Perforation A Danish population-based cohort study. *Diabetes Care* 2006;29:805-810.
- ⁹⁴ Halbritter K, Beyer J, Oettler W, Schellong S. Register zur Erfassung von Komplikationen unter Vitamin-K-Antagonisten. P267, Abstract GTH Jahrestagung 2006, Basel 15.-17.02.2006.
- ⁹⁵ Oehler G, Kemkes-Matthes B. Blutgerinnung und Thrombose. *Thrombose-Schriftreihe* 1991; Sandoz AG Nürnberg